clomipramine has been researched along with Behavior Disorders in 22 studies
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-five adult subjects with severe morbid onychophagia (nail biting) and no history of obsessive-compulsive disorder were enrolled in a 10-week double-blind cross-over trial of clomipramine hydrochloride and desipramine hydrochloride." | 5.07 | A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). ( Lenane, MC; Leonard, HL; Rapoport, JL; Rettew, DC; Swedo, SE, 1991) |
| "Clomipramine was superior to desipramine in the acute treatment of body dysmorphic disorder symptoms as measured by assessment of patients' obsessive preoccupation with perceived body defects, repetitive behaviors in response to this preoccupation, and global ratings of symptom severity." | 2.69 | Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. ( Allen, A; Aronowitz, B; Hollander, E; Kwon, J; Schmeidler, J; Simeon, D; Wong, C, 1999) |
| "Some of the psychiatric disorders that are usually comorbid with dermatological disorders and respond to antidepressants include major depressive disorder, obsessive compulsive disorder, body dysmorphic disorder, social phobia and post-traumatic stress disorder usually secondary to trauma and abuse during early life." | 2.41 | The use of antidepressant drugs in dermatology. ( Gupta, MA; Guptat, AK, 2001) |
| " TDM and pharmacogenetic tests are useful tools to improve pharmacotherapy by preventing dose-dependent adverse drug events, optimizing dosage during long-term treatment and identifying ultrarapid metabolizers and malcompliance." | 1.33 | [Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry]. ( Etzensberger, M; Jaquenoud Sirot, E; Stephan, PL, 2006) |
| "To investigate the relationship between 5-HTT occupancy and a wide range of antidepressant dosing protocols." | 1.32 | High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ( Ichimiya, T; Ikoma, Y; Inoue, M; Okubo, Y; Sudo, Y; Suhara, T; Takano, A; Yasuno, F, 2003) |
| "Clomipramine is a tricyclic antidepressant that has been recommended for the treatment of canine compulsive disorder." | 1.30 | The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ( Ball, RO; Conlon, PD; Hewson, CJ; Luescher, UA, 1998) |
| "Trichotillomania is a chronic illness that may be difficult to treat." | 1.29 | Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study. ( Aronowitz, B; Cohen, LJ; Hollander, E; Rosen, J; Simeon, D; Spadaccini, E; Stein, DJ, 1995) |
| " Data in adult patients illustrate on the one hand possible causes of variability in plasma levels of haloperidol and, on the other hand, the fact that poor bioavailability is not the cause of lack of response in 'resistant' schizophrenic patients." | 1.26 | Clinical significance of monitoring plasma levels of psychotropic drugs. ( Morselli, PL; Zarifian, E, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (31.82) | 18.7374 |
| 1990's | 10 (45.45) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ross, S | 1 |
| Fallon, BA | 1 |
| Petkova, E | 1 |
| Feinstein, S | 1 |
| Liebowitz, MR | 1 |
| Suhara, T | 1 |
| Takano, A | 1 |
| Sudo, Y | 1 |
| Ichimiya, T | 1 |
| Inoue, M | 1 |
| Yasuno, F | 1 |
| Ikoma, Y | 1 |
| Okubo, Y | 1 |
| Janowsky, DS | 1 |
| Shetty, M | 1 |
| Barnhill, J | 1 |
| Elamir, B | 1 |
| Davis, JM | 1 |
| Stephan, PL | 1 |
| Etzensberger, M | 1 |
| Jaquenoud Sirot, E | 1 |
| Morselli, PL | 2 |
| Bianchetti, G | 1 |
| Dugas, M | 1 |
| Fischer, W | 1 |
| Rabending, G | 1 |
| Heydenreich, F | 1 |
| Herzer, H | 1 |
| Altenstein, R | 1 |
| Grimmberger, E | 1 |
| Kühne, GE | 1 |
| Grünes, JU | 1 |
| Stöck, H | 1 |
| Shimoda, K | 2 |
| Noguchi, T | 2 |
| Ozeki, Y | 1 |
| Morita, S | 1 |
| Shibasaki, M | 1 |
| Someya, T | 1 |
| Takahashi, S | 2 |
| Cohen, LJ | 1 |
| Stein, DJ | 1 |
| Simeon, D | 2 |
| Spadaccini, E | 1 |
| Rosen, J | 1 |
| Aronowitz, B | 2 |
| Hollander, E | 2 |
| Minowada, T | 1 |
| Herpertz-Dahlmann, B | 1 |
| Leonard, HL | 2 |
| Swedo, SE | 2 |
| Lenane, MC | 2 |
| Rettew, DC | 2 |
| Hamburger, SD | 1 |
| Bartko, JJ | 1 |
| Rapoport, JL | 3 |
| Amsterdam, JD | 1 |
| García-España, F | 1 |
| Rosenzweig, M | 1 |
| Hewson, CJ | 1 |
| Conlon, PD | 1 |
| Luescher, UA | 1 |
| Ball, RO | 1 |
| Allen, A | 1 |
| Kwon, J | 1 |
| Schmeidler, J | 1 |
| Wong, C | 1 |
| Gupta, MA | 1 |
| Guptat, AK | 1 |
| Zarifian, E | 1 |
| Zapletálek, M | 1 |
| Hübsch, T | 1 |
| Zbytovský, J | 1 |
| Polácková, J | 1 |
| Kindernayovä, H | 1 |
| Brock-Utne, JG | 1 |
| Cheetham, RW | 1 |
| Goodwin, NM | 1 |
| Cole, EN | 1 |
| Groom, GV | 1 |
| Link, J | 1 |
| O'Flanagan, PM | 1 |
| Seldrup, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ascending-Dose, Double-Blind, Placebo-Controlled, Bilateral Study of Intralesional Fluphenazine Decanoate in Psoriasis[NCT00356200] | Phase 2 | 10 participants (Actual) | Interventional | 2006-07-31 | Terminated (stopped due to Enrollment criteria met) | ||
| Ascending-Dose, Double-Blind, Placebo-Controlled, Study of Intralesional Fluphenazine Hydrochloride for Psoriasis[NCT00929578] | Phase 2 | 15 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 4 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis). (NCT00356200)
Timeframe: Baseline to week 4
| Intervention | mm (Mean) |
|---|---|
| Cohort 1, 10 ug/ml Fluphenazine Treated Lesion | -30 |
| Cohort 1, Placebo Treated Lesion | -27.2 |
| Cohort 2, 100 ug/ml Fluphenazine Treated Lesion | -18 |
| Cohort 2, Placebo Treated Lesion | -32.6 |
Change in score from 0-14 of target lesion disease activity based on scaling, erythema, and induration as determined by a physician assessor at week 4 compared to baseline (with 0 being no disease activity and 14 being maximum disease activity). (NCT00356200)
Timeframe: Baseline to week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Cohort 1, 10 ug/ml Fluphenazine Treated Lesion | -1 |
| Cohort 1, Placebo Treated Lesion | -0.8 |
| Cohort 2, 100 ug/ml Fluphenazine Treated Lesion | -0.4 |
| Cohort 2, Placebo Treated Lesion | -1.5 |
Actual change in target lesion score comparing 4 week score with baseline score. Improvement is positive, worsening is negative. Target lesions scores range from 0 (no disease) to 12 (severe disease), and are scored based on the sum of erythema (0-4), induration (0-4) and scale (0-4) scores. (NCT00929578)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -1.4 |
| Fluphenazine | -1.4 |
Visual Analog Scale (VAS) score for pruritus. Subjective measurement of pruritus on an analog scale with a single mark denoting self-perceived pruritus: Minimum 0mm for no itch, Maximum 100mm for worst itch imaginable. Scores are measured in millimeters. This secondary outcome is a percentage improvement from baseline score for pruritus. Improvement is negative, worsening is positive. (NCT00929578)
Timeframe: 4 weeks
| Intervention | percentage of baseline pruritus (Mean) |
|---|---|
| Placebo | 0.86 |
| Fluphenazine | -2.16 |
Number of participants with fluphenazine serum levels > 0.200ng/ml, at baseline, 2 hours post dose and 1 week post dose. (NCT00929578)
Timeframe: 1 week
| Intervention | participants (Number) |
|---|---|
| Baseline | 0 |
| 2 Hours Post Dose | 2 |
| 1 Week Post Dose | 2 |
adverse events will be recorded and monitored. Adverse events will be noted in a separate chart. (NCT00929578)
Timeframe: 8 weeks
| Intervention | All Study Participant (Number) |
|---|---|
| All Study Participants | 12 |
2 reviews available for clomipramine and Behavior Disorders
| Article | Year |
|---|---|
[Serotonergic antidepressants--indications for treating children and adolescents exemplified by fluoxetine and clomipramine].
Topics: Adolescent; Child; Clomipramine; Fluoxetine; Humans; Mental Disorders | 1993 |
The use of antidepressant drugs in dermatology.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Mental | 2001 |
The use of antidepressant drugs in dermatology.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Mental | 2001 |
The use of antidepressant drugs in dermatology.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Mental | 2001 |
The use of antidepressant drugs in dermatology.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Mental | 2001 |
6 trials available for clomipramine and Behavior Disorders
| Article | Year |
|---|---|
Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation.
Topics: Adolescent; Adult; Aged; Biotransformation; Clomipramine; Dealkylation; Drug Interactions; Female; G | 1995 |
A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents.
Topics: Adolescent; Adult; Age Factors; Behavior Therapy; Child; Clomipramine; Cohort Studies; Combined Moda | 1993 |
Clomipramine augmentation in treatment-resistant depression.
Topics: Adult; Aged; Akathisia, Drug-Induced; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Sq | 1997 |
Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.
Topics: Adrenergic Uptake Inhibitors; Adult; Clomipramine; Comorbidity; Cross-Over Studies; Delusions; Desip | 1999 |
[Clinical and experimental experiences with maprotiline, clomipramine, sydnocarb and mefexamide in mentally-ill patients and in healthy persons].
Topics: Adult; Anthracenes; Clinical Trials as Topic; Clomipramine; Depression; Dibenzazepines; Female; Glyc | 1977 |
A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting).
Topics: Adult; Ambulatory Care; Clomipramine; Desipramine; Dose-Response Relationship, Drug; Double-Blind Me | 1991 |
14 other studies available for clomipramine and Behavior Disorders
| Article | Year |
|---|---|
Long-term follow-up study of patients with refractory obsessive-compulsive disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Clomipramine; Drug Resistance; Female; Follow-U | 2008 |
High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.
Topics: Adult; Antidepressive Agents, Tricyclic; Carrier Proteins; Clomipramine; Dose-Response Relationship, | 2003 |
Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial.
Topics: Adolescent; Adult; Aged; Aggression; Antidepressive Agents; Attention Deficit and Disruptive Behavio | 2005 |
[Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry].
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bio | 2006 |
Therapeutic drug monitoring of psychotropic drugs in children.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Child; Child | 1983 |
[Use possibilities of quantitative electroencephalography in psychiatry and psychopharmacology].
Topics: Cerebral Cortex; Clomipramine; Delayed-Action Preparations; Double-Blind Method; Electroencephalogra | 1982 |
[Operational evaluation studies in psychopharmacological research (presented with an example of a comparison between clomipramine and tisocromide)].
Topics: Clomipramine; Computers; Heterocyclic Compounds; Humans; Mental Disorders; Oxathiins; Psychometrics; | 1980 |
Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study.
Topics: Adolescent; Adult; Age Distribution; Age of Onset; Behavior Therapy; Child; Child, Preschool; Clomip | 1995 |
Interindividual variations of desmethylation and hydroxylation of clomipramine in an Oriental psychiatric population.
Topics: Adolescent; Adult; Aged; Biotransformation; Clomipramine; Dose-Response Relationship, Drug; Ethnicit | 1993 |
The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine.
Topics: Administration, Oral; Animals; Antidepressive Agents, Tricyclic; Clomipramine; Dog Diseases; Dogs; G | 1998 |
Clinical significance of monitoring plasma levels of psychotropic drugs.
Topics: Adult; Child; Chronic Disease; Clomipramine; Haloperidol; Humans; Mental Disorders; Parasympatholyti | 1979 |
Psychiatric problems in intensive care. Five patients with acute confusional states and depression.
Topics: Adult; Aged; Clomipramine; Cognition Disorders; Confusion; Consciousness Disorders; Critical Care; D | 1976 |
Plasma prolactin concentrations in patients on clomipramine.
Topics: Clomipramine; Dibenzazepines; Female; Humans; Male; Mental Disorders; Prolactin | 1976 |
Treatment of behavioral disorders in animals.
Topics: Animal Diseases; Animals; Animals, Domestic; Clomipramine; Desipramine; Disease Models, Animal; Dog | 1990 |